Vaccine Prevention of Rheumatic Fever
风湿热疫苗预防
基本信息
- 批准号:7490667
- 负责人:
- 金额:$ 47.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAcuteAcute PharyngitisAddressAdjuvantAdultAfricaAnimalsAntibodiesAntibody FormationAntigensBiological AssayCellsCenters for Disease Control and Prevention (U.S.)Cervical lymph node groupChildChronicClinical DistributionClinical ResearchCombined VaccinesConsensusCountryDNADataDeveloped CountriesDeveloping CountriesDevelopmentDiseaseDoseDrug FormulationsEnzyme-Linked Immunosorbent AssayEpidemiologyFacility Construction Funding CategoryFundingGenesGoalsGuanosine MonophosphateHealthHeart DiseasesImmune responseIn VitroIncidenceIndividualIndustryInfectionIntramuscularLaboratory StudyLipid ALiposomesLymphocyte ActivationMarylandMedical SurveillanceMononuclearMusNicaraguaNorth AmericaOne-Step dentin bonding systemPeptidesPharyngeal structurePharyngitisPhasePhase I Clinical TrialsPlasmidsPrevalencePreventionProductionProspective StudiesProteinsProtocols documentationPublishingRecombinant VaccinesRecombinantsReportingResearchResearch PersonnelRheumatic FeverRheumatic Heart DiseaseRouteSafetySalivaScheduleSelection CriteriaSerotypingSerumSiteSourceSpleenStandards of Weights and MeasuresStreptococcal InfectionsStreptococcal VaccinesStreptococcusStreptococcus pyogenesSubunit VaccinesT-LymphocyteT-Lymphocyte EpitopesTestingToxic effectTranslatingUniversitiesUpper armVaccine DesignVaccinesWestern EuropeWorkaluminum sulfatebasecytokinedesigndesign and constructionenzyme linked immunospot assayexperienceimmunogenicimmunogenicityimprovedintraperitoneallymph nodesmembermouse modelmulticatalytic endopeptidase complexmultiple myeloma M Proteinnovel vaccinespreclinical studypreventprogramsprototyperecombinant peptideresearch clinical testingresearch studyresponsevaccine deliveryvaccine efficacyvolunteer
项目摘要
The overall goal of this project is to develop a safe and effective multivalent M protein-base d vaccine to prevent acute rheumatic fever (ARF). Rheumatic fever is triggered by group A streptococcal infections of the throat. Although the incidence of ARF has declined markedly in the U.S. and other developed countries over the past 50 years, the disease remains rampant in developing countries of the world. Rheumatic heart disease (RHD) is the leading cause of heart disease in children throughout the world. An estimated 12 million people suffer from chronic RHD and 400,000 die from the disease each year. Thus, the development of an effective vaccine designed to prevent the streptococcal infections that cause ARF and RHD could significantly improve the health of millions of children around the world. The aims of this proposal are: 1) To
determine the distribution of group A streptococcal serotypes causing acute pharyngitis in countries where ARF is common, 2) to determine the optimal formulation and route of delivery of multivalent group A streptococcal vaccines using an established mouse model, 3) to identify T cell epitopes within multivalent vaccines in order to enhance the overall protective antibody responses to the multivalent vaccines, 4) to translate these findings into the design, construction, GMP production, and formulation of a multivalent vaccine to prevent rheumatic fever, and 5) to perform a phase I clinical trial to assess the safety and immunogenicity of the vaccine in adult volunteers. Prospective studies will be conducted in Mall, West Africa
and Leon, Nicaragua to identify the prevalent rheumatogenic serotypes. This information will be combined with available data on the emm-type distribution of clinical isolates from around the world. Laboratory studies in animals will establish the optimal formulation and route of delivery for the vaccine. The final vaccine will be produced and manufactured to GMP standards by ID Biomedical Corporation. The proposed phase I clinical trial will be performed at the University of Maryland and will establish the safety and immunogenicity of the vaccine in human adult volunteers. Successful completion of these studies will bring us one step closer to determining whether acute rheumatic fever is a vaccine preventable disease.
该项目的总体目标是开发一种安全有效的多价M蛋白碱D疫苗,以防止急性风湿热(ARF)。风湿热是由A组的喉咙链球菌感染引起的。尽管在过去50年中,美国和其他发达国家的ARF发生率显着下降,但在世界发展中国家中,该疾病仍然猖ramp。风湿性心脏病(RHD)是全世界儿童心脏病的主要原因。估计每年有1200万人患有慢性RHD和40万人死亡。因此,开发旨在防止引起ARF和RHD的链球菌感染的有效疫苗可以显着改善世界上数百万儿童的健康。该提议的目的是:1)
确定A组链球菌血清型的分布,在ARF很常见的国家中引起急性咽炎,2)确定多价组A链球菌疫苗的最佳配方和途径,使用已建立的小鼠模型,3),以鉴定多价疫苗,以增强跨性别抗体反应,以增强综合抗体反应,以增强量的抗体反应。设计,建筑,GMP的生产和多价疫苗的制剂以防止风湿发烧,以及5)进行I期临床试验,以评估成人志愿者中疫苗的安全性和免疫原性。前瞻性研究将在西非购物中心进行
尼加拉瓜莱昂(Leon),以识别流变的风湿性血清型。该信息将与有关来自世界各地的临床分离株的EMM型分布的可用数据结合使用。动物的实验室研究将建立疫苗的最佳配方和输送途径。最终的疫苗将由ID Biomedical Corporation生产和制造,按GMP标准生产。拟议的I期临床试验将在马里兰大学进行,并将在人类成人志愿者中建立疫苗的安全性和免疫原性。这些研究的成功完成将使我们更接近确定急性风湿热是否是可预防的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES B. DALE其他文献
JAMES B. DALE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES B. DALE', 18)}}的其他基金
Structure-Based Design of a Broadly Protective Group A Streptococcal Vaccine
基于结构的广泛保护群 A 链球菌疫苗的设计
- 批准号:
10183147 - 财政年份:2017
- 资助金额:
$ 47.06万 - 项目类别:
Group A Streptococcal Vaccine Containing Immunogenic Peptides of Streptolysin S
含有链球菌溶血素S免疫原性肽的A组链球菌疫苗
- 批准号:
9044727 - 财政年份:2015
- 资助金额:
$ 47.06万 - 项目类别:
Chemistry and Immunology of Streptococcal M Proteins
链球菌 M 蛋白的化学和免疫学
- 批准号:
8128102 - 财政年份:2010
- 资助金额:
$ 47.06万 - 项目类别:
17th Lancefield International Symposium on Streptococci and Streptococcal Disease
第十七届兰斯菲尔德国际链球菌和链球菌疾病研讨会
- 批准号:
7483861 - 财政年份:2008
- 资助金额:
$ 47.06万 - 项目类别:
Vaccine Prevention of Group A Streptococcal Infections
A 组链球菌感染的疫苗预防
- 批准号:
8232727 - 财政年份:1996
- 资助金额:
$ 47.06万 - 项目类别:
Chemistry and Immunology of Streptococcal M Proteins
链球菌 M 蛋白的化学和免疫学
- 批准号:
7625116 - 财政年份:1996
- 资助金额:
$ 47.06万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
An RNA vaccines systems approach to Group A streptococcus vaccine discovery
发现 A 组链球菌疫苗的 RNA 疫苗系统方法
- 批准号:
10577082 - 财政年份:2023
- 资助金额:
$ 47.06万 - 项目类别:
Strep-CaDI: A fast, accurate, and sensitive point-of-care test for Group A Streptococcus
Strep-CaDI:快速、准确且灵敏的 A 组链球菌现场检测
- 批准号:
10699852 - 财政年份:2023
- 资助金额:
$ 47.06万 - 项目类别:
急性上気道炎の咽頭痛に対するトラネキサム酸の効果の検証
氨甲环酸治疗急性上呼吸道炎症引起的咽喉痛的疗效验证
- 批准号:
23K14725 - 财政年份:2023
- 资助金额:
$ 47.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
- 批准号:
10577066 - 财政年份:2023
- 资助金额:
$ 47.06万 - 项目类别:
Investigating CovRS activation within skin microenvironments to drive heterogenicity of Streptococcus pyogenes gene expression
研究皮肤微环境中的 CovRS 激活以驱动化脓性链球菌基因表达的异质性
- 批准号:
10751462 - 财政年份:2023
- 资助金额:
$ 47.06万 - 项目类别: